High SMAD4 Expression is Associated With Improved Clinical Outcomes in Patients With Resectable Pancreatic Cancer: An Analysis of NRG Oncology/RTOG 9704.
Terence M Williams, Jennifer Moughan, William F Regine, Cynthia D Timmers, Ryan Robb, Tiantian Cui, Thomas A DiPetrillo, Nick C Leasure, Hyun Kim, Desiree E Doncals, Samir Narayan, David A Bush, Lauren E Henke, Guila Delouya, Michael G Haddock, Kathryn Winter, Chandan Guha, Edgar Ben-Josef
Int J Radiat Oncol Biol Phys S0360-3016(26)04310-5
摘要
摘要
PURPOSE: The SMAD4 transcription factor mediates transforming growth factor β signal transduction and is frequently inactivated in pancreatic cancer (PC). This study evaluated SMAD4 (protein) expression in the NRG Oncology/RTOG 9704 phase 3 trial comparing postoperative chemotherapy-chemoradiation combination regimens for resectable PC. It is hypothesized that higher SMAD4 expression correlates with lower distant metastasis (DM) and improved overall survival (OS). METHODS AND MATERIALS: Quantitative multiplexed SMAD4 immunofluorescence analysis was performed in pan-cytokeratin-positive tumor samples from resected specimens. Total cellular SMAD4 analysis was dichotomized by the median (low: <median, high: ≥median). Disease-free survival (DFS) and OS were evaluated by Kaplan-Meier methods and log-rank tests. Local-regional recurrence and DM were assessed via cumulative incidence and Gray's tests. SMAD4-outcome associations were evaluated by univariate and multivariable Cox proportional hazards or Fine-Gray regression models. RESULTS: For 141 analyzable patients, baseline characteristics remained similar with and without SMAD4 quantitation and between low and high SMAD4 groupings. High SMAD4 expression was associated with better DFS (32% risk reduction of DFS failure [hazard ratio {HR} (95% CI), 0.68 (0.48, 0.97); P = .03]), improved OS (31% risk reduction of death [HR {95% CI}, 0.69 (0.48, 0.99); P = .04]), and lower DM rates (HR [95% CI], 0.69 [0.48, 0.99], P = .048), but not local-regional recurrence. Multivariable analysis confirmed correlations between high SMAD4 and better DFS (HR [95% CI], 0.66 [0.46, 0.96], P = .03) and lower DM rate ([HR {95% CI}, 0.68 [0.46, 1.004], P = .052). CONCLUSIONS: SMAD4 expression is significantly associated with lower DM and higher DFS and OS in tumor samples from a large, prospectively randomized trial of resectable PC.
KM 提取结果
0 个 Figure · 0 个 KM 面板